Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer

Meta-analysis of two randomized controlled phase 3 trials compared abiraterone acetate plus prednisolone with or without enzalutamide added to ADT (combination therapy group) versus ADT alone (control group) for high-risk non-metastatic prostate cancer. The combination therapy group had significantly longer metastasis-free survival, overall survival, prostate cancer-specific survival, biochemical failure-free survival, and progression-free survival. There were seven grade 5 AEs among 986 patients in the combination therapy group versus none in the control group. The authors conclude that abiraterone acetate with prednisolone added to ADT should be considered a new standard treatment for high-risk non-metastatic prostate cancer.